N/A N=28 Dopamine and Insulin Resistance
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=181 Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery
Hemostasis
Primary: Proportion of Subjects Achieving Hemostasis by Five Minutes After Treatment Start at the TBS — 75.0; 75.0; 73.9; 82.5 percent of subjects achieving hemostasis
Phase 2 N=27 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Adult Diffuse Large B-Cell Lymphoma · B-Cell Non-Hodgkin Lymphoma · Follicular Lymphoma
Primary: Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant — 19 Participants
N/A N=64 Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial
Tricuspid Valve Regurgitation · Tricuspid Valve Insufficiency
Primary: Change in the Degree of Tricuspid Regurgitation — 27; 18; 6; 6 participants
N/A N=121 Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease
Intestinal Disease · Inflammatory Bowel Disease · Crohn Disease
Primary: Normal vs Abnormal, Overall Impression — 42; 42; 72; 72 participants — p=1.0000
Phase 2 N=68 Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Inflammatory Breast Cancer · Male Breast Cancer · Stage II Breast Cancer
Primary: Microscopic Pathologic CR (pCR) Rate — 27 percent of evaluable participants
Phase 2 N=21 Neoadjuvant Pazopanib in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Response Rate — 8 Participants
N/A N=4 TMS for CRPS - Pilot Study
Complex Regional Pain Syndrome (CRPS)
Primary: Change in Pain — 5.2; 0.7 units on a scale
Phase 4 N=37 Pioglitazone in Patients With Mood Disorders
Major Depressive Disorder · Insulin Resistance
Primary: Hamilton Depression Rating Scale at Baseline — 15.22; 13.67; 19.22; 13.25 units on a scale
Phase 2 N=120 Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: (Phase I) Maximum Tolerated Dose of Stereotactic Body Radiotherapy (SBRT) as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 — 12.0 Gy/FX
Phase 2 N=7 Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder (OCD)
Primary: Scores Change in Yale-Brown Obsessive Compulsive Challenge Scale (YBOCCS) Scores From Baseline to 230 Minutes Postinfusion. — 13.71 units on a scale
Phase 3 N=153 Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0; 96.6; 96.3 percentage of participants
Phase 2 N=43 Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
Dumping Syndrome
Primary: Response Rate in Plasma Glucose Level — 60.5 percentage of participants
Phase 2 N=13 Effect of Baclofen on Marijuana Withdrawal and Relapse
Marijuana Dependence
Primary: Measure of Relapse: Change in Money Spent Between Baseline and Relapse Phase — 7.15; 9.77; 7.25 dollars spent on marijuana
Phase 2 N=32 Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Rectal Cancer · Adenocarcinoma of the Rectum
Primary: Maximum Tolerated Dose (MTD) of Erlotinib When Administered in Combination With 5-fluorouracil (5-FU), Bevacizumab, and External Beam Radiation Therapy — 100 mg